Oxfordshire Innovation Engine 2023 Case Study – Immunocore

The next case study from our Oxfordshire Innovation Engine 2023 is here. In this study, we look at commercial biotechnology research company, Immunocore.

Immunocore develops novel therapies that harness our immune system by using T Cell Receptor (TCRs) biology to fight cancer, infectious diseases and autoimmune conditions, using science that originated from research conducted at Oxford University.

Researchers at the company develop, what they call, ImmTAX™ (Immune Mobilizing Monoclonal TCRs Against X disease) molecules. The idea of the ‘X’ is that the technology can be used to target cancers and other diseases, using the same approach.

These molecules are designed to get around the challenge that the body’s natural immune system is not always able to do what it is meant to do, because cancers and infectious diseases are adept at hiding from it or, in the case of autoimmune diseases, the immune system attacks the body. They work by helping the body detect cancer or disease and encourage the immune system to kickstart a patient’s natural defences, for cancer and infectious diseases, or control them, for autoimmune conditions.

When the Innovation Engine update report of 2016 last covered Immunocore, it had scientific partnership arrangements with Genentech (a Roche company), GSK, Medimmune (owned by AstraZeneca) and Eli Lilly. Trials were reported as providing positive early results.

Since then, partnerships may have changed, but the positive results have continued. In 2022, Immunocore received FDA and EMA approval for its treatment for Uveal Melanoma (a cancer that affects the eye). It is the company’s first commercialised treatment, the first TCR therapy approved, as well as the first approved treatment for the condition.  The drug is now approved for use in around thirty countries. Discussions with NICE are ongoing to establish if the treatment can be made available in the UK on the NHS.

You can read the full case study on our Innovation Engine page

 

Recent news

Grove Business Park joins Advanced Oxford

Grove Business Park joins Advanced Oxford

Advanced Oxford is delighted to welcome Grove Business Park in Wantage as a new sponsor member, who will be actively contributing to our work in supporting the development of Oxfordshire’s innovation ecosystem. Grove Business Park is owned by The Oxford Endowment Fund...

read more
Green Light for YASA’s new Bicester Motion UK HQ

Green Light for YASA’s new Bicester Motion UK HQ

Detailed designs for three new interconnected buildings which will be YASA’s new UK HQ based at Bicester Motion, the future mobility estate in Bicester Oxfordshire, have been approved by Cherwell District Council.   YASA, a spin-out from the University of Oxford...

read more
Loading...